|Medical Services||Locations||Patient/Visitor Info||Programs & Support||Points of Pride|
Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
PURPOSE: This randomized phase III trial is studying rosuvastatin (Crestor) to see how well it works compared with placebo in treating patients with stage I, II or III colon cancer that was removed by surgery.
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether rosuvastatin is more effective than a placebo in treating colon cancer that was removed by surgery.
OUTLINE: This is a multicenter study sponsored by the National Cancer Institute. Patients are divided according to family history of a first-degree relative with colorectal cancer (yes vs no), intended aspirin dose (none vs 81 mg vs 325 mg), and adjuvant therapy for colon cancer (yes vs no). Patients are randomized (given an equal chance to receive) 1 of 2 treatment arms.
Tumor tissue, serum, and blood samples may be collected periodically for biomarker and other analyses.
After completion of study treatment, patients are followed up periodically for up to 2 years.
FOR FURTHER INFORMATION CONTACT STUDY NURSES
Nona Blauvelt MSN, AOCN 610-738-2522
Blanche Reiner RN, OCN 610-738-2515
Last Updated: 3/19/2014